TCGA-OL-A66K-01A-11R-A29R-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 42
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.370
- MYOGENESIS+0.300
- ESTROGEN_RESPONSE_EARLY+0.230
- WNT_BETA_CATENIN_SIGNALING+0.190
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.140
- ESTROGEN_RESPONSE_LATE+0.130
- APICAL_JUNCTION+0.120
- ANGIOGENESIS+0.110
- BILE_ACID_METABOLISM+0.080
- XENOBIOTIC_METABOLISM+0.070
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- G2M_CHECKPOINT-0.510
- INTERFERON_GAMMA_RESPONSE-0.500
- E2F_TARGETS-0.490
- ALLOGRAFT_REJECTION-0.460
- COMPLEMENT-0.420
- MTORC1_SIGNALING-0.410
- MYC_TARGETS_V1-0.390
- IL6_JAK_STAT3_SIGNALING-0.350
- INFLAMMATORY_RESPONSE-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A5ZX-01A-12R-A29R-07 | — | A | 0.879 |
| 2 | AUR-AEPZ-TTP1-A-1-1-R-A742-41 | — | B | 0.878 |
| 3 | TCGA-W8-A86G-01A-21R-A36F-07 | — | A | 0.875 |
| 4 | TCGA-A2-A04N-01A-11R-A115-07 | — | A | 0.871 |
| 5 | SRR25617855 | — | A | 0.869 |
| 6 | TCGA-AR-A5QP-01A-11R-A28M-07 | — | A | 0.868 |
| 7 | SRR25617932 | — | A | 0.862 |
| 8 | TCGA-E2-A570-01A-11R-A29R-07 | — | B | 0.860 |
| 9 | TCGA-GM-A3XG-01A-31R-A24H-07 | — | A | 0.858 |
| 10 | C3L-01890 | — | cohortA2 | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.040 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.020 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.010 | Inavolisib | — uncovered |